U.S. Generally Accepted Accounting Principles (GAAP) require that this agreement be recorded in the third quarter, as it occurred after the October 19 release of the Company's third quarter financial results and before the filing of the Company's Quarterly Report on Form 10-Q. Accordingly, the Company has updated its financial results for the third quarter and nine months ended September 30, 2009, recording a third quarter charge of $294 million, on both a pre-tax and after-tax basis. This amount represents the $296 million charge associated with the agreement net of a $2 million reversal of a related accrual.

"We are pleased this investigation has been resolved," said Ray Elliott, President and Chief Executive Officer of Boston Scientific. "Guidant and its employees acted in good faith and believed they complied with applicable laws and regulations. We elected to resolve this matter so we could put it behind us and devote our full energies and resources to developing our innovative technologies."

The only products involved in the investigation were the VENTAK PRIZM((R)) 2, the CONTAK RENEWAL((R)) and the CONTAK RENEWAL 2 devices, which were the subjects of the 2005 product advisories.

The table below reconciles the Company's updated third quarter and year-to-date 2009 financial results to those previously reported. The adjustments in the table are also reflected in the Company's Form 10-Q, which will be filed later today.

                                                    Q3 2009 Results
                                             ------------------------------
                                                       Litigation-
                                            Previously   Related      As
    (in millions, except per share data)     Reported     Charge    Updated
    ------------------------------------     --------     ------    -------
    Income (loss) before income taxes          $250       $(294)      $(44)
    Net income (loss)                          $200       $(294)      $(94)

    GAAP EPS                                  $0.13      $(0.19)    $(0.06)
    Adjusted EPS                              $0.19                  $0.19

                                                   Q3 2009 YTD Results
                                             ------------------------------
                                                       Litigation-
                                            Previously   Related      As
    (in millions, except per share data)     Reported     Charge    Updated
    ------------------------------------     --------     ------    -------
    Income before income taxes                 $333       $(294)       $39
    Net income                                 $345       $(294)       $51

    GAAP EPS                                  $0.23      $(0.20)     $0.03
    Adjusted EPS                              $0.58                  $0.58

In addition, the Company has updated its full-year 2009 GAAP earnings per share guidance as a result of recording this charge. The Company now expects net income on a GAAP basis of $0.23 to $0.28 per share for the full year ending December 31, 2009. The Company continues to expect adjusted earnings -- excluding intangible asset impairment charges; acquisition-, divestiture-, and litigation-related net charges; restructuring and restructuring-related costs; discrete tax items; and amortization expense -- of between $0.75 and $0.79 per share. The table below reconciles the Company's updated full-year guidance to that previously reported.

                                                 2009 Full-year Guidance
                                             ------------------------------
                                                       Litigation-
                                            Previously   Related      As
                                             Reported     Charge    Updated
                                             --------     ------    -------
    GAAP EPS - low                            $0.43      $(0.20)     $0.23
    GAAP EPS - high                           $0.48      $(0.20)     $0.28

    Adjusted EPS - low                        $0.75                  $0.75
    Adjusted EPS - high                       $0.79                  $0.79

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding financial performance, resolution of government proceedings, regulatory compliance and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

Use of non-GAAP Financial Information

A reconciliation of the Company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the Company's use of these non-GAAP measures, is included in the exhibits attached to this press release.

                           BOSTON SCIENTIFIC CORPORATION
        NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS
                                    (Unaudited)


                                      Three Months Ended September 30, 2009
                                      -------------------------------------
                                         Previously
                                          Reported            As Updated
                                         -----------          ----------
                                               Impact                 Impact
                                                 per        Net         per
    In millions, except per share      Net     diluted     (loss)     diluted
     data                             income    share      income      share
    -----------------------------     ------    -----      ------      -----
    GAAP results                       $200      $0.13       $(94)    $(0.06)
    Non-GAAP adjustments:
        Restructuring-related
         charges                         21       0.01         21       0.01
        Litigation-related net
         (credits) charges              (37)     (0.02)       257       0.17*
        Amortization expense            107       0.07        107       0.07*
                                        ---       ----        ---       ----
    Adjusted results                   $291      $0.19       $291      $0.19
                                       ====      =====       ====      =====

    * Assumes dilution of 10.9 million shares for all or a portion of these
      amounts.


                                       Nine Months Ended September 30, 2009
                                       ------------------------------------
                                        Previously
                                          Reported           As Updated
                                        -----------          ----------
                                               Impact                 Impact
                                                 per                   per
    In millions, except per share      Net     diluted      Net       diluted
     data                             income    share      income      share
    -----------------------------     ------    -----      ------      -----
    GAAP results                       $345      $0.23        $51      $0.03
    Non-GAAP adjustments:
        Intangible asset impairment
         charges                          8       0.01          8       0.01
        Acquisition-related charges      17       0.01         17       0.01
        Divestiture-related gains        (2)     (0.00)        (2)     (0.00)
        Restructuring-related
         charges                         69       0.05         69       0.05
        Litigation-related net
         charges                        203       0.13        497       0.33
        Discrete tax items              (74)     (0.05)       (74)     (0.05)
        Amortization expense            312       0.20        312       0.20
                                        ---       ----        ---       ----
    Adjusted results                   $878      $0.58       $878      $0.58
                                       ====      =====       ====      =====

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

                          BOSTON SCIENTIFIC CORPORATION
       NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS
                                      (CONT.)
                                   (Unaudited)

                                   Three Months Ended     Nine Months Ended
                                   September 30, 2009    September 30, 2009
                                   ------------------    ------------------
                                  Previously     As     Previously     As
                                    Reported   Updated    Reported   Updated
                                  -----------  -------  -----------  -------
    Intangible asset impairment
     charges:
      Intangible asset impairment
       charges                                                  $10      $10
          Less: Income tax
           benefit (a)                                           (2)      (2)
                                                                 --       --
    Intangible asset impairment
     charges, net of tax                                         $8       $8
                                                                 ==       ==

    Acquisition-related charges:
      Purchased research and
       development                                              $17      $17
          Less: Income tax
           benefit (a)
                                                                ---      ---
    Acquisition-related charges,
     net of tax                                                 $17      $17
                                                                ===      ===

    Divestiture-related gains:
      Net gain on sale of
      investments (b)                                           $(3)     $(3)
          Less: Income tax
           expense (a)                                            1        1
                                                                 --       --
    Divestiture-related gains,
     net of tax                                                 $(2)     $(2)
                                                                ===      ===

    Restructuring-related charges:
      Restructuring charges                $9       $9          $44      $44
      Restructuring-related
       charges (c)                         19       19           50       50
                                           --       --           --       --
                                           28       28           94       94
          Less: Income tax
           benefit (a)                     (7)      (7)         (25)     (25)
                                           --       --          ---      ---
    Restructuring-related
     charges, net of tax                  $21      $21          $69      $69
                                          ===      ===          ===      ===

    Litigation-related net
     (credits) charges:
      Litigation-related credits         $(58)    $(58)        $(58)    $(58)
      Litigation-related charges                   294          287      581
                                          ---      ---          ---      ---
                                          (58)     236          229      523
          Less: Income tax
           expense (benefit) (a)           21       21          (26)     (26)
                                           --       --          ---      ---
    Litigation-related net
     (credits) charges, net of
     tax                                 $(37)    $257         $203     $497
                                         ====     ====         ====     ====

    Discrete tax items:
                                                               ----     ----
      Discrete tax items                                       $(74)    $(74)
                                                               ====     ====

    Amortization expense:
      Amortization expense               $126     $126         $381     $381
          Less: Income tax
           benefit (a)                    (19)     (19)         (69)     (69)
                                          ---      ---          ---      ---
    Amortization expense, net of
     tax                                 $107     $107         $312     $312
                                         ====     ====         ====     ====

    (a) Amounts are tax effected at the Company's effective tax rate, unless
        the amount is a significant unusual or infrequently occurring item in
        accordance with FASB Accounting Standards Codification section
        740-270-30, "General Methodology and Use of Estimated Annual
        Effective Tax Rate."
    (b) Recorded to other, net.
    (c) In the third quarter of 2009, recorded $13 million to cost of
        products sold; $5 million to selling, general and administrative
        expenses; and $1 million to research and development expenses. In the
        third quarter of 2008, recorded $4 million to cost of products sold;
        $9 million to selling, general and administrative expenses; and $1
        million to research and development expenses. In the first nine
        months of 2009, recorded $36 million to cost of products sold; $11
        million to selling, general and administrative expenses; and $3
        million to research and development expenses. In the first nine
        months of 2008, recorded $11 million to cost of products sold; $24
        million to selling, general and administrative expenses; and $5
        million to research and development expenses.

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document

                            BOSTON SCIENTIFIC CORPORATION
             ESTIMATED NON-GAAP NET INCOME PER COMMON SHARE RECONCILIATIONS
                                   (Unaudited)

                                             2009 Estimate  2009 Estimate
                                                     (Low)         (High)
    GAAP results                                     $0.23         $0.28

    Estimated intangible asset impairment
     charges                                          0.01          0.01
    Estimated acquisition-related net
     credits                                         (0.11)        (0.11)
    Estimated restructuring-related charges           0.07          0.06
    Estimated litigation-related net charges          0.33          0.33
    Estimated discrete tax items                     (0.05)        (0.05)
    Estimated amortization expense                    0.27          0.27

    Adjusted results                                 $0.75         $0.79

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

Use of Non-GAAP Financial Measures

To supplement Boston Scientific's condensed consolidated financial statements presented on a GAAP basis; the Company discloses certain non-GAAP measures that exclude certain amounts, including non-GAAP net income, non-GAAP net income per share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange. These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States.

The GAAP measure most comparable to non-GAAP net income is GAAP net income and the GAAP measure most comparable to non-GAAP net income per share is GAAP net income per share. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP measure are included in the accompanying schedules.

To calculate regional and divisional revenue growth rates that exclude the impact of foreign exchange, the Company converts actual current-period net sales from local currency to U.S. dollars using constant foreign exchange rates. The GAAP measure most comparable to this non-GAAP measure is growth rate percentages based on GAAP revenue. A reconciliation of this non-GAAP financial measure to the corresponding GAAP measure is included in the accompanying schedules.

Use and Economic Substance of Non-GAAP Financial Measures Used by Boston Scientific

Management uses these supplemental non-GAAP measures to evaluate performance period over period, to analyze the underlying trends in the Company's business, to assess its performance relative to its competitors, and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP measures to further its understanding of the performance of the Company's operating segments. The adjustments excluded from the Company's non-GAAP measures are consistent with those excluded from its reportable segments' measure of profit or loss. These adjustments are excluded from the segment measures that are reported to the Company's chief operating decision maker and are used to make operating decisions and assess performance.

The following is an explanation of each of the adjustments that management excluded as part of its non-GAAP measures for the nine months ended September 30, 2009 and 2008 and for the forecasted three month period and full year ending December 31, 2009, as well as reasons for excluding each of these individual items:

    --  Intangible asset impairment charges - These amounts represent non-cash
        write-downs of certain of the Company's intangible assets. Following the
        Company's acquisition of Guidant in 2006, and the related increase in
        the Company's debt, management has heightened its focus on cash
        generation and debt pay down. Management removes the impact of these
        charges from the Company's operating performance to assist in assessing
        the Company's cash generated from operations. Management believes this
        is a critical metric for the Company in measuring the Company's ability
        to generate cash and pay down debt. Therefore, these charges are
        excluded from management's assessment of operating performance and are
        also excluded from the measures management uses to set employee
        compensation. Accordingly, management believes this may be useful
        information to users of its financial statements and therefore has
        excluded these charges for purposes of calculating these non-GAAP
        measures to facilitate an evaluation of the Company's current operating
        performance, particularly in terms of liquidity.

    --  Acquisition-related net charges (credits) - These adjustments consist of
        purchased research and development and a gain resulting from the receipt
        of an acquisition-related milestone payment. Purchased research and
        development is a highly variable charge based on the extent and nature
        of external technology acquisitions during the period. The
        acquisition-related milestone received in the third quarter of 2008 is
        one of two receipts the Company expects to receive as a result of
        Guidant Corporation's sale of its vascular intervention and endovascular
        solutions businesses to Abbott Laboratories and is not indicative of
        future operating results. Management removes the impact of these charges
        (credits) from the Company's operating results to facilitate an
        evaluation of the Company's current operating performance and a
        comparison to the Company's past operating performance.

    --  Divestiture-related gains and losses - These amounts represent gains and
        losses, and related tax impacts, that the Company recognized related to
        the sale of non-strategic assets, including the sale of certain
        businesses, development programs and non-strategic investments. The sale
        and transfer of these non-strategic assets were substantially completed
        during 2008. These gains and losses are not indicative of future
        operating performance and are not used by management to assess operating
        performance. Accordingly, management excluded these amounts for purposes
        of calculating these non-GAAP measures to facilitate an evaluation of
        the Company's current operating performance and a comparison to the
        Company's past operating performance.

    --  Restructuring and restructuring-related costs - These adjustments
        primarily represent severance, employee-related retention incentives,
        asset write-offs, accelerated depreciation, costs to transfer production
        lines from one facility to another, and other costs associated with the
        Company's Plant Network Optimization and 2007 Restructuring plans. These
        expenses are not indicative of the Company's on-going operating
        performance and are excluded by management in assessing the Company's
        operating performance, as well as from the Company's operating segments'
        measures of profit and loss used for making operating decisions and
        assessing performance. Accordingly, management excluded these charges
        for purposes of calculating these non-GAAP measures to facilitate an
        evaluation of the Company's current operating performance and a
        comparison to the Company's past operating performance.

    --  Litigation-related charges -These amounts represent significant charges
        related to litigation. During the third quarter of 2009, the Company
        recorded a pre-tax charge of $294 million associated with a U.S.
        Department of Justice investigation. Also during the third quarter of
        2009, the Company recorded a pre-tax credit of $58 million associated
        with the reduction of previously recorded reserves related to certain
        other litigation matters. In addition, the Company recorded pre-tax
        charges of $287 million during the first quarter of 2009 and $334
        million during the third quarter of 2008 associated with certain patent
        litigation matters. Management does not believe these items reflect
        expected on-going operating expenses. Accordingly, management excluded
        these (credits) charges for purposes of calculating these non-GAAP
        measures to facilitate an evaluation of the Company's current operating
        performance and for comparison to the Company's past operating
        performance.

    --  Discrete tax items - These items represent current period adjustments of
        certain tax positions, which were initially established in prior periods
        as a result of acquisitions or as a result of divestiture- and
        litigation-related charges, or restructuring and restructuring-related
        costs. These adjustments do not reflect expected on-going operating
        results. Accordingly, management excluded these amounts for purposes of
        calculating these non-GAAP measures to facilitate an evaluation of the
        Company's current operating performance and for comparison to the
        Company's past operating performance.

    --  Amortization expense - Amortization expense is a non-cash charge and
        does not impact the Company's liquidity or compliance with the covenants
        included in its debt agreements. Management removes the impact of
        amortization from the Company's operating performance to assist in
        assessing the Company's cash generated from operations. Management
        believes this is a critical metric for the Company in measuring the
        Company's ability to generate cash and pay down debt. Therefore,
        amortization expense is excluded from management's assessment of
        operating performance and is also excluded from the measures management
        uses to set employee compensation. Accordingly, management believes this
        may be useful information to users of its financial statements and
        therefore has excluded amortization expense for purposes of calculating
        these non-GAAP measures to facilitate an evaluation of the Company's
        current operating performance, particularly in terms of liquidity.

    --  Foreign exchange on net sales - The impact of foreign exchange is highly
        variable and difficult to predict. Accordingly, management excludes the
        impact of foreign exchange for purposes of reviewing regional and
        divisional revenue growth rates to facilitate an evaluation of the
        Company's current operating performance and comparison to the Company's
        past operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

Non-GAAP net income, non-GAAP net income per diluted share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange may have limitations as analytical tools, and these non-GAAP measures should not be considered in isolation from or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are:

    --  Items such as purchased research and development, gains on
        acquisition-related milestones and divestiture-related gains and losses
        reflect economic costs and benefits to the Company and are not reflected
        in non-GAAP net income and non-GAAP net income per diluted share.

    --  Items such as restructuring and restructuring-related costs,
        litigation-related (credits) charges, and discrete tax items that are
        excluded from non-GAAP net income and non-GAAP net income per diluted
        share can have a material impact on cash flows and GAAP net income and
        net income per diluted share.

    --  Amortization expense and intangible asset impairment charges, though not
        directly affecting Boston Scientific's cash flow position, represent a
        reduction in value of intangible assets. The expense associated with
        this reduction in value is not included in Boston Scientific's non-GAAP
        net income or non-GAAP net income per diluted share and therefore these
        measures do not reflect the full effect of the reduction in value of
        those intangible assets.

    --  Revenue growth rates stated on a constant currency basis, by their
        nature, exclude the impact of foreign exchange, which may have a
        material impact on GAAP net sales.

    --  Other companies may calculate non-GAAP net income, non-GAAP net income
        per diluted share, or regional and divisional revenue growth rates that
        exclude the impact of foreign exchange differently than Boston
        Scientific does, limiting the usefulness of those measures for
        comparative purposes.

Compensation for Limitations Associated with Use of Non-GAAP Financial Measures

Boston Scientific compensates for the limitations on its non-GAAP financial measures by relying upon its GAAP results to gain a complete picture of the Company's performance. The non-GAAP numbers focus instead upon the core business of the Company, which is only a subset, albeit a critical one, of the Company's performance.

The Company provides detailed reconciliations of each non-GAAP financial measure to its most directly comparable GAAP measure in the accompanying schedules, and Boston Scientific encourages investors to review these reconciliations.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting non-GAAP net income, non-GAAP net income per share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange in addition to the related GAAP measures provides investors greater transparency to the information used by Boston Scientific management for its financial and operational decision-making and allows investors to see Boston Scientific's results "through the eyes" of management. The Company further believes that providing this information better enables Boston Scientific's investors to understand the Company's operating performance and to evaluate the methodology used by management to evaluate and measure such performance.

    CONTACT: Paul Donovan
             508-650-8541 (office)
             508-667-5165 (mobile)
             Media Relations
             Boston Scientific Corporation

             Larry Neumann
             508-650-8696 (office)
             Investor Relations
             Boston Scientific Corporation

SOURCE Boston Scientific Corporation

http://www.bostonscientific.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

SmarTrend is bearish on shares of BSX and our subscribers received a Downtrend alert on October 02, 2009 at $10.07, which has returned 21.2% to date.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

(Photo: http://www.newscom.com/cgi-bin/prnh/20091102/NY02934 )

The Company will begin marketing the PROMUS Element system immediately in the European Union and other CE Mark countries. CE Mark was granted by the Dutch Notified Body KEMA Quality B.V.

The platinum chromium alloy used in the PROMUS Element stent is engineered specifically for coronary stenting. This proprietary alloy offers greater radial strength and flexibility than older alloys such as the cobalt chromium alloy used in the XIENCE PRIME(TM) DES, and it provides enhanced visibility and reduced recoil. The innovative stent design improves deliverability and allows for more consistent lesion coverage and drug distribution. The advanced catheter delivery system further improves deliverability.

"The platinum chromium alloy and new stent design used in the PROMUS Element stent represent significant innovations in drug-eluting stent technology," said Bruno Farah, M.D., Clinique Pasteur, Toulouse, France. "In my experience, the Element platform offers a stenting option that provides superior deliverability and visibility with excellent comformability and low recoil. I believe it offers performance improvements that could simplify procedures and allow treatment of a broader range of patients."

In addition to the PROMUS Element Everolimus-Eluting Coronary Stent System, the Company plans to offer the TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System. Both Element systems incorporate the platinum chromium alloy with the innovative stent design and advanced catheter delivery system.

"We are proud to introduce our third-generation drug-eluting stent to physicians and patients in Europe and other CE Mark countries," said David McFaul, Boston Scientific Senior Vice President, International. "The PROMUS Element system is the latest example of Boston Scientific's commitment to DES market leadership and continued innovation. We also plan to launch the TAXUS Element system in CE Mark countries next year, giving physicians the choice of two proven drug and polymer combinations - used in millions of patients worldwide - on an entirely new stent platform. We are confident our Element series will further extend our global DES leadership."

The PROMUS Element system is being evaluated in the PLATINUM clinical trial, which completed enrollment of 1,532 patients in September at more than 140 sites worldwide. PLATINUM is a randomized, controlled, pivotal trial designed to support U.S. Food and Drug Administration (FDA) and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the PROMUS Element system. The TAXUS Element system is being evaluated in the PERSEUS trial, which completed enrollment in October 2008 and will report primary endpoint data at the American College of Cardiology conference in March.

The Company anticipates FDA approval for the PROMUS Element system in 2012. The TAXUS Element system was launched in select international markets in May. CE Mark approval for the TAXUS Element system is expected in the second quarter of 2010, and FDA approval is expected in 2011.

In the U.S., the PROMUS Element and TAXUS Element systems are investigational devices and are limited by applicable law to investigational use only and are not available for sale.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings, product performance and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    Press Contact:
    Paul Donovan
    Media Relations
    Boston Scientific Corporation
    508-650-8541 (office)
    508-667-5165 (mobile)

    Larry Neumann
    Investor Relations
    Boston Scientific Corporation
    508-650-8696 (office)

SOURCE Boston Scientific